Tharimmune Q1 2025 Earnings Report

Tharimmune EPS Results

• Actual EPS: -$0.99
• Consensus EPS: -$0.84
• Beat/Miss: Missed by -$0.15
• One Year Ago EPS: N/A

Tharimmune Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tharimmune Announcement Details

• Quarter: Q1 2025
• Date: 5/12/2025
• Time: Before Market Opens
• Conference Call Date: Sunday, May 11, 2025
• Conference Call Time: 6:00PM ET

Tharimmune (NASDAQ:THAR) is a clinical-stage biotechnology company dedicated to developing novel immuno-activating therapies for life-threatening infectious, inflammatory and hemorrhagic conditions. The company employs a proprietary platform of synthetic innate immune receptor agonists, designed to harness and amplify the body’s natural defenses against bacterial infections, sepsis and related organ injuries. Tharimmune’s lead program targets acute conditions where rapid activation of innate immunity can reduce pathogen burden, curb systemic inflammation and improve clinical outcomes.

Founded in 2016 and headquartered in Seattle, Washington, Tharimmune emerged from academic collaborations with leading immunologists and infectious disease researchers. The company’s pipeline includes multiple preclinical candidates optimized for potency, safety and manufacturability. Their flagship TLR4 agonist is being advanced toward IND-enabling studies for sepsis and acute kidney injury, while additional programs focused on TLR7/8 and STING pathways seek to address multidrug-resistant pneumonia and hemorrhagic shock. Tharimmune’s synthetic molecules are designed for scalable chemical synthesis and have demonstrated robust activity in animal models.

Tharimmune maintains strategic partnerships with academic centers and contract research organizations across North America and Europe to accelerate development and manufacturing. The company’s research approach integrates immunology expertise with process chemistry, enabling rapid iteration on lead scaffolds and streamlined transition to GMP production. In parallel, Tharimmune collaborates with regulatory consultants to design adaptive clinical trial protocols and engage early with the U.S. Food and Drug Administration and the European Medicines Agency.

The leadership team at Tharimmune combines seasoned biopharma executives, infectious disease specialists and process development experts. The board and executive management draw on decades of experience from global pharmaceutical companies, academic research institutions and government agencies. Together, they guide Tharimmune’s mission to deliver first-in-class immunotherapies that address urgent unmet needs in critical care and infectious disease management.